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Abstract
Inconsistent results for the role of dairy food intake in relation to ovarian cancer risk may reflect
the potential adverse effects of lactose, which has been hypothesized to increase gonadotropin
levels, and the beneficial anti-proliferative effects of calcium and vitamin D. Using data from the
New England case-control study (1909 cases; 1989 controls) we examined dairy foods and
nutrients in relation to risk of ovarian cancer overall, histological subtypes, and rapidly fatal
versus less aggressive disease. We used logistic regression and polytomous logistic regression to
estimate odds ratios and 95% confidence intervals. In models that were simultaneously adjusted
for total (dietary plus supplements) calcium, total vitamin D and lactose, we observed a decreased
overall risk of ovarian cancer with high intake of total calcium (Quartile 4 (Q4, >1319 mg/day) vs.
Quartile 1 (Q1, <655 mg/day), odds ratio (OR)=0.62, 95% Confidence Interval (CI)=0.49 – 0.79);
the inverse association was strongest for serous borderline and mucinous tumors. High intake of
total vitamin D was not associated overall with ovarian cancer risk, but was inversely associated
with risk of serous borderline (Q4, >559 IU/day vs. Q1, <164 IU/day, OR=0.51, 95% CI=0.34–
0.76) and endometrioid tumors (Q4 vs. Q1, OR=0.55, 95% CI=0.39-0.80). We found no evidence
that lactose intake influenced ovarian cancer risk, or that risk varied by tumor aggressiveness in
the analyses of intake of dairy foods and nutrients. The overall inverse association with high
intake of calcium, and the inverse associations of calcium and vitamin D with specific histological
subtypes warrant further investigation.
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Introduction
Differences in ovarian cancer incidence rates worldwide1 suggest that lifestyle factors,
including diet, may play an important role in risk for this disease. The observation that per
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capita milk consumption and lactase persistence (the ability to digest lactose after
childhood) is significantly positively correlated with ovarian cancer incidence worldwide
highlights the potential role of dairy food consumption in ovarian carcinogenesis2. It has
been hypothesized that the galactose component of dairy sugar or lactose might have a toxic
effect on oocytes and prematurely raise gonadotropins in a similar manner to that observed
in mouse/rat models where high lactose diets led to ovulatory disfunction and
hypogonadism3–5.
Subsequent epidemiologic studies that evaluated consumption of dairy foods or lactose in
relation to ovarian cancer risk produced conflicting results with case-control studies
generally finding a null association6 while cohort studies showed a more consistent positive
association between high intake of lactose6–8 and/or skim/low fat milk7 or milk (all types)6
and risk of ovarian cancer.
Inconsistencies could be due to the contrasts of intake that were examined, potential
differences in the distribution of histological subtypes across studies, or may reflect
differences in long term versus recent dairy food consumption or in the types of dairy
products consumed and their different nutrient contents. We hypothesized that foods higher
in lactose or fats could have a more harmful effect while foods with higher levels of calcium
or vitamin D might be beneficial by down-regulation of circulating parathyroid hormone
leading to decreased cell proliferation9, 10. In this large population-based case-control study
of ovarian cancer, we evaluated intake of dairy foods and their components (lactose,
calcium, vitamin D) in relation to ovarian cancer risk overall, the main histological subtypes,
and rapidly fatal versus less aggressive disease.
Materials and Methods
Study population
Details regarding case and control enrollment in the New England case-control (NECC)
study were described previously11, 12. Briefly, 3957 women residing in eastern
Massachusetts or New Hampshire with a diagnosis of incident ovarian cancer were
identified through hospital tumor boards and statewide cancer registries. Of these, 3083
(78%) cases met eligibility criteria and 2203 (71%) were enrolled. This analysis was
restricted to 2076 cases with epithelial tumors. Controls were identified through random
digit dialing, drivers' license lists and town resident lists. In the first study phase (1992–
1997), 420 (72%) and 102 (51%) of the eligible controls identified through random digit
dialing and town resident lists, respectively, agreed to participate. In the second (1998–
2003) and third (2003–2008) phases, 4366 potential controls were identified of whom 2940
(67%) were eligible; 1362 (46%) declined to participate by phone or by mail via an “opt-
out” postcard and 1578 (54%) were enrolled. Controls were frequency matched to cases on
age and state of residence. Study participants were interviewed in-person at the time of
enrollment about known and putative ovarian cancer risk factors that occurred at least one
year before diagnosis (for cases) or enrollment (controls). Institutional review boards at the
Brigham and Women’s Hospital and the Dartmouth Medical School approved the study and
all participants provided written informed consent.
Tumor histological subtype and behavior (invasive vs. borderline) was abstracted from
pathology reports that had been reviewed by a gynecologic pathologist. We examined five
major histological subtypes of ovarian cancer; serous borderline or invasive, mucinous,
endometrioid and clear cell tumors. We also evaluated invasive ovarian cancer cases by
tumor aggressiveness (rapidly fatal and less aggressive) based on the time interval between
diagnosis and death reported in the National Death Index. Rapidly fatal cases were those
who died due to any cause within 3 years (the cause of death was unavailable) and less
Merritt et al. Page 2
Int J Cancer. Author manuscript; available in PMC 2014 March 01.
$watermark-text
$watermark-text
$watermark-text
aggressive cases were those who died >3 years post-diagnosis or those who were alive at
follow-up.
Diet assessment
Dietary intake that occurred at least one year before diagnosis or study enrollment was
assessed at the time of enrollment using a semi-quantitative food frequency questionnaire
(FFQ)13, 14 which has been previously shown to provide valid estimates of skim/low fat
milk, whole milk and yogurt intake with correlation coefficients between the dietary
questionnaire and the 1-week diet records of 0.81, 0.62 and 0.94, respectively15. For
calcium, correlation coefficients of 0.56 with supplements and 0.51 without supplements
were reported between the dietary questionnaire and 1-week diet records16. For vitamin D,
reported intake via the dietary questionnaire and plasma concentrations of 25-OH vitamin D
were moderately correlated (correlation coefficients of 0.35 and 0.25 with and without
supplements, respectively)17.
Specific dairy foods that were assessed for this study included skim/low fat milk, whole
milk, cream, sour cream, non-dairy coffee whitener, sherbet/ice milk, ice cream, yogurt,
cottage/ricotta cheese, other cheeses and butter. Additional food items that are important
sources of calcium, including broccoli and leafy green vegetables, also were included in the
FFQ. The questionnaire included questions on supplemental vitamin usage; for
multivitamins respondents were asked about the number of pills per week and the specific
brand and for single supplements respondents were asked about the dosage per day and the
duration of use. Dietary nutrient intake (lactose, calcium and vitamin D) was calculated by
multiplying the frequency of intake of each food containing the nutrient by the nutrient
content of specified portions determined from the food composition values available from
the U.S. Department of Agriculture food composition data18. In order to provide information
about the primary dietary sources of each nutrient, we confirmed that there were similar
frequencies of intake of dairy foods in the NECC and the Nurses’ Health Study (NHS)
which also is comprised of U.S. residents and diet was assessed over a similar time period7.
In the NHS in 2002, the primary dietary sources of lactose were skim/ low fat milk (63%)
and yogurt (15%), the main dietary sources of calcium were skim/low fat milk (29%),
fortified orange juice (8%) and hard cheeses (7%), and the major dietary sources of vitamin
D were fortified skim/low fat milk (41%) and fish (32%) (S. Tworoger, personal
communication). Total (dietary and supplemental) nutrient intake was calculated by
summing the contributions of the nutrient from dietary, multivitamin and single supplement
sources. Intakes of total and saturated fat were calculated as the sum of the contributions
from all foods based on the U.S. Department of Agriculture data and also included
margarine and fats used in cooking or baking.
Statistical analysis
Individuals were excluded from the analysis if they did not complete a food frequency
questionnaire (n = 134) or if they had an implausibly low or high caloric intake (<500 or
>3500 kcals/day) (n = 143). Energy-adjusted nutrient intake was calculated using the
residuals from the regression of nutrient intake based on a total caloric intake of 1600 kcal/
day19. Nutrient quartile cutpoints were calculated based on the distribution of intake among
controls. Unconditional logistic regression was used to estimate the odds ratio and 95%
confidence intervals for the main effects of dairy foods and nutrients. All multivariable
analyses were adjusted for age (continuous), number of pregnancies (continuous), oral
contraceptive use (0, >3 months-2 yrs, >2–5 yrs, >5–10 yrs, >10 yrs), tubal ligation (yes,
no), family history of ovarian cancer in a first degree relative (yes, no), study center (MA,
NH), study phase (1,2,3) and energy intake (continuous). Analyses of lactose intolerance
were additionally adjusted for race. To simultaneously evaluate the effects of lactose, total
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calcium and total vitamin D, we included all three terms in the same regression model.
Additional potential confounders were evaluated but not included in the final models
because they did not substantially alter the risk estimates. We calculated Pearson correlation
coefficients (r) to assess co-linearity between continuous nutrient variables. Tests for linear
trend were performed using the Wald test with a trend variable based on the median number
of servings/day for each category of dairy food intake or using a trend variable based on the
median value for each quartile (for dairy nutrients). We assessed effect modification by age
(< 50, ≥ 50 years), menopausal status (unknown or pre-menopause, post-menopause), body
mass index (< 25, ≥ 25), oral contraceptive use (ever/never), parity and median total fat
intake (high, low). The P for interaction was calculated using a likelihood ratio test to
compare models with and without interaction terms.
Polytomous logistic regression (PLR) was used to simultaneously estimate separate risk
factor associations across 1) histological subtypes and 2) rapidly fatal versus less aggressive
invasive ovarian cancers. For PLR, the likelihood ratio test was used to calculate a P-value
for heterogeneity comparing a model in which all of the associations were held constant
between the case subgroups to a model which allowed only the association of interest to
differ between the case subgroups20. In all statistical analyses a P-value < 0.05 was
considered as significant. Analyses were performed using SAS v9.2 (SAS Institute Inc.,
Cary, NC) and Stata v9 (StataCorp, College Station, Texas).
Results
The final study population included 1909 women with epithelial ovarian cancer (invasive
and borderline) and 1989 controls. Cases reported a lower proportion and shorter duration of
oral contraceptive (OC) use, were less likely to be parous or to have had a tubal ligation and
were more likely to report a family history of ovarian cancer (Table 1). Consumption of
selected dairy products (yogurt, cottage/ricotta cheese and hard cheeses) was significant and
inversely related to risk of ovarian cancer and all showed a trend (P ≤ 0.02) of decreasing
risk with increasing intake (Table 2, Model 1). Increased consumption of skim/low fat milk
also was inversely associated with ovarian cancer risk although only an intermediate
category of intake was statistically significant (2–7 times/week vs. never/less than monthly,
Odds Ratio (OR) = 0.83, 95% CI, 0.70 – 0.97, Ptrend = 0.28). In contrast, we observed an
increased risk of ovarian cancer with high intake of whole milk (≥ 2 times/week vs. never/
less than monthly, OR = 1.43, 95% CI, 1.15 – 1.78, Ptrend = 0.002) or cream cheese (≥ 2
times/week vs. never/< monthly, OR = 1.39, 95% CI, 1.09 – 1.77, Ptrend = 0.008). We
observed a non-significant positive association between consumption of ice cream and
ovarian cancer risk. In additional analyses of dairy foods with a higher fat content (whole
milk, hard cheeses, cottage/ricotta cheese, ice cream and cream cheese), additionally
adjusting for quartiles of total fat intake (Table 2, Model 2) only minimally altered the risk
estimates. Quartiles of total fat and saturated fat intake were not associated with risk of
ovarian cancer overall (data not shown).
The energy-adjusted intake of both dietary and total calcium and vitamin D was higher in
controls while lactose intake was similar in cases and controls (Table 1). We observed a
statistically significant inverse association with ovarian cancer risk with higher intake of
both dietary and total (dietary plus supplements) calcium and vitamin D (Table 3, Model 1).
The protective effects for intake of total calcium (Quartile 4 (Q4) vs. Q1, OR = 0.61, 95%
CI, 0.50 – 0.74, Ptrend < 0.001) and total vitamin D (Q4 vs. Q1, OR = 0.76, 95% CI, 0.63 –
0.92, Ptrend = 0.01) were slightly stronger than for dietary intake of either nutrient. We
observed a non-significant inverse association for high intake of lactose with ovarian cancer
risk (Q4 vs. Q1, OR = 0.88, 95% CI, 0.73 – 1.05, Ptrend = 0.07). Dietary intake of calcium
and lactose were strongly correlated (r = 0.89) as was dietary intake of vitamin D with
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lactose or calcium (both correlations r = 0.54). When all three nutrients were included in the
same multivariable model (Table 3, Model 2), we observed a similar inverse association for
total calcium intake and risk of ovarian cancer (Q4 vs. Q1, OR = 0.62, 95% CI, 0.49 – 0.79,
Ptrend < 0.001) however the odds ratio for the highest compared with the lowest quartile of
total vitamin D intake was attenuated (Q4 vs. Q1, OR = 0.93, 95% CI, 0.74 – 1.16, Ptrend =
0.75).
We evaluated the association of intake of total calcium, total vitamin D and lactose with
ovarian cancer risk among participants who were < age 50 or ≥ age 50. For participants who
were < age 50, any category of calcium intake that was higher than the referent group had a
significantly protective effect (e.g., Q4 vs. Q1, OR = 0.56, 95% CI, 0.39 – 0.80, Ptrend =
0.002). Among participants who were ≥ age 50, only the highest quartile of calcium intake
was significantly protective (Q4 vs. Q1, OR = 0.69, 95% CI, 0.54 – 0.87, Ptrend < 0.001)
(Pint = 0.01) (Table 4). Associations were similar for total vitamin D intake with ovarian
cancer risk across both age groups (Pint = 0.41). For lactose intake among participants who
were < age 50, we observed a statistically significant inverse association with ovarian cancer
risk for any category of intake that was higher than the referent group (e.g., Q4 vs. Q1, OR =
0.70, 95% CI, 0.52 – 0.95, Ptrend = 0.04) while there was no association between lactose
intake and ovarian cancer risk among participants who were ≥ age 50 (Pint = 0.01). We
observed similar results to those reported using the age 50 cutoff in analyses stratified by
menopausal status (pre/dubious menopause vs. postmenopausal) (data not shown). In
analyses of dairy food and nutrient intake, similar estimates to the overall findings were
observed when participants were stratified by parity, OC use, body mass index and median
total fat or saturated fat intake (data not shown).
In an earlier report we observed an excess of controls who reported lactose intolerance
beginning at an early age (< age 20). Consistent with this finding, we evaluated the
association with lactose intolerance beginning before age 20 and found a suggestive inverse
association with ovarian cancer risk (OR = 0.72, 95% CI, 0.42 – 1.22). We did not observe
any association with ovarian cancer risk for individuals who reported lactose intolerance
beginning at or after age 20 (OR = 0.96, 95% CI, 0.75 – 1.22) (data not shown). As a crude
measure of lactose intolerance we also asked respondents about their use of lactase enzyme
tablets/lactose-free dairy products and observed a non-significant inverse association with
reported use of these products (OR = 0.87, 95% CI, 0.67 – 1.12).
We identified significant differences in the risk associations for intake of total calcium and
total vitamin D across the histological subtypes (using polytomous logistic regression (PLR)
combined with the likelihood ratio test to calculate a P-value for heterogeneity, Phet (model)
≤ 0.04) (Table 5). The strongest inverse associations for total calcium intake were observed
in serous borderline (Q4 vs. Q1, OR = 0.41, 95% CI, 0.27 – 0.62, Ptrend < 0.001) and
mucinous tumors (Q4 vs. Q1, OR = 0.46, 95% CI, 0.29 – 0.72, Ptrend < 0.001). The ORs
associated with total calcium intake remained essentially unchanged after additional
adjustment for total vitamin D and lactose (data not shown).
The strongest inverse associations for total vitamin D intake were observed in the serous
borderline (Q4 vs. Q1, OR = 0.51, 95% CI, 0.34 – 0.76, Ptrend = 0.001) and endometrioid
tumors (Q4 vs. Q1, OR = 0.55, 95% CI, 0.39 – 0.80, Ptrend = 0.002) (Table 5). In the model
that was mutually adjusted for all three nutrients, risk estimates for total vitamin D intake
were slightly attenuated but remained significantly protective for serous borderline (Q4 vs.
Q1, OR = 0.61, 95% CI, 0.40 – 0.93, Ptrend = 0.02) and endometrioid tumors (Q4 vs. Q1,
OR = 0.66, 95% CI, 0.45 – 0.97, Ptrend = 0.046) (data not shown). We observed no
difference in the associations between lactose intake and risk of the different histological
subtypes of ovarian cancer (Phet (model) = 0.66). In analyses assessing intake of individual
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dairy foods, ORs for the histological subtypes resembled those for ovarian cancer risk
overall (data not shown).
Based on previous suggestions that high intake of dairy-related factors was modestly
associated with poorer survival, we evaluated whether the risk associations with dairy food
and/or nutrient consumption varied between rapidly fatal and less aggressive invasive cases
as compared with controls using the time interval between the date of diagnosis to the date
of death to define rapidly fatal (died within 3 years of diagnosis) and less aggressive (died
>3 years post-diagnosis or still alive) cases. We observed no statistically significant
differences in risk by tumor aggressiveness (rapidly fatal vs. less aggressive invasive
tumors) in the analyses of intake of dairy foods and nutrients (data not shown). Further
adjustment for tumor stage made no difference to the risk associations. In the subset of cases
for which detailed chemotherapy data were available (n=946), the majority (90% and 84%)
of the rapidly fatal and less aggressive cases, respectively, were treated with a cisplatin and/
or carboplatin regimen (data not shown).
Discussion
In this updated analysis of the NECC21 (including 1909 cases and 1989 controls), we
evaluated the association of intake of dairy foods and nutrients (including calcium and
vitamin D) in relation to ovarian cancer risk overall and assessed whether these associations
differed among the histological subtypes of ovarian cancer. Consistent with previous case-
control studies9, 22–24, we observed that high intake of skim/low fat milk was significantly
inversely associated with ovarian cancer risk. Among three additional case-control studies
that evaluated consumption of any type of milk, two studies reported an inverse association
between high milk intake and ovarian cancer risk25, 26 and the third study found no
association27. In contrast, three cohort studies reported a suggestive but non-significant
increased risk of invasive ovarian cancer with high consumption of skim/low fat milk7, 28 or
any type of milk29 while another cohort study30 and a pooled analysis of 12 cohort studies8
found no association with intake of any type of milk. In separate analyses of whole milk, we
observed that high intake was associated with significantly increased risk of ovarian cancer.
This finding is consistent with previous case-control studies23, 24 and some7 but not all8, 31
cohort studies.
We found that high intake of yogurt and ricotta/cottage cheese was significantly inversely
associated with ovarian cancer risk. In contrast, previous case-control and cohort studies
reported no association between consumption of yogurt and/or ricotta/cottage cheese and
ovarian cancer risk7–9, 22, 29, 30 and one study23 reported an elevated risk with increasing
consumption of full fat (but not low fat) yogurt. We were unable to distinguish low fat from
full fat yogurt in our study. We observed that high consumption of hard cheeses was
significantly inversely associated with risk of ovarian cancer. This result is consistent with
the Nurses’ Health Study7 but not with other studies that reported no association8, 9, 28–30 or
an increased risk23 with high cheese intake. To our knowledge this was the first report that
high intake of cream cheese was associated with increased ovarian cancer risk. The
increased risk that we observed for selected high-fat foods was unlikely to be due to their fat
content because total fat and saturated fat intake alone were not associated with ovarian
cancer risk in our study. There have been conflicting findings regarding the association
between total fat intake and ovarian cancer risk; a meta-analysis of seven case-control and
one cohort study32 and a recent report from the NIH-AARP Diet and Health Study33 found
significantly increased risk with high total fat intake while a pooled analysis of 12 cohort
studies found no association with total fat intake34.
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A component of dairy foods that has been hypothesized to increase ovarian cancer risk is
lactose (and its metabolite galactose) through toxic effects on the ovarian germ cells leading
to subsequent gonadotropin stimulation of the ovaries35. In support of this, most7, 8, 28, 29
but not all30, 31 cohort studies reported a positive association between lactose intake and
ovarian cancer risk and two of these studies reported a stronger association for serous
invasive tumors7, 29. In contrast, case-control studies, including the current report, have
found little evidence for an association between lactose intake and ovarian cancer
risk6, 21, 23, 36–39 and one study reported a significant inverse association9. We did not
observe differences in the association with lactose intake across the histological subtypes.
It has been suggested that differences in the association between lactose intake and ovarian
cancer risk in case-control and cohort studies may relate to the time periods measured by the
dietary questionnaire (i.e., recent diet in case-control studies versus long-term or baseline
diet in cohort studies)6. Although we were unable to evaluate diet in an earlier life period in
our study, we observed a non-significant but suggestive inverse association with ovarian
cancer risk among individuals who reported symptoms of lactose intolerance that began
before the age of 20 and did not observe an association if symptoms began at or after age 20.
Considering that lactose intolerant women are likely to consume less lactose, this finding
suggests that decreased lactose intake early in life may reduce ovarian cancer risk although
further studies are needed to confirm this finding.
We also evaluated intake of calcium and vitamin D in relation to ovarian cancer risk and
identified a significant inverse association and dose-response with higher dietary or total
(diet plus supplements) intake of either nutrient. We observed a stronger protective effect for
total calcium and total vitamin D as compared with dietary intake of either nutrient alone
and attributed this to the higher intake among individuals who use supplements. Due to the
high correlations observed for these dairy nutrients, it was difficult to identify independent
associations with ovarian cancer risk. Nevertheless, in models that were mutually adjusted
for total calcium, total vitamin D and lactose intake, the statistically significant inverse
association with total calcium intake remained unchanged, while the association with total
vitamin D intake was attenuated and no longer significant. Findings of an inverse
association between dietary and/or total calcium intake and ovarian cancer risk are
consistent with some9, 31 but not all28 previous studies, and a pooled analysis of cohort
studies found no association8. We also observed that the association with calcium intake was
influenced by the participant’s age. For women aged ≥ 50 only the highest quartile of
calcium intake was significantly inversely associated with ovarian cancer in women, while
any intake higher than the referent category was protective for ovarian cancer in younger (<
50 years) women, possibly due to the role of estrogens in enhancing intestinal calcium
absorption40.
In our data total calcium was inversely associated with serous borderline and mucinous
tumors. Higher levels of calcium intake have been postulated to reduce ovarian cancer risk
by inhibiting the release of parathyroid hormone which may have pro-tumorigenic effects by
stimulating IGF-19, 10. Our observation that mucinous tumors showed a strong inverse
association with total calcium intake was of interest because intestinal type mucinous
ovarian tumors have been recognized41 and recent studies have suggested that advanced
stage ovarian mucinous carcinomas could be metastases from the colorectum42 and the
protective effects for colorectal cancer with increased calcium intake are well established43.
Together these observations suggest that calcium intake may influence the risk of
developing a mucinous neoplasm regardless of the primary tumor site, although these results
require further confirmation.
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We also found that high intake of total vitamin D was inversely associated with risk of
serous borderline and endometrioid tumors. Complementary to our results, a pooled analysis
of four studies (including the current study) found that the VDR Fok1 polymorphism,
leading to reduced functionality of the VDR, was strongly associated with increased risk of
serous borderline and endometrioid tumors44. However, a recent pooled analysis of five
additional studies observed an increased risk of ovarian cancer (all types) among carriers of
the variant VDR Fok1 allele but they did not observe a difference in the association by
tumor histology45. In contrast to our findings, the pooled analysis of cohort studies reported
a non-significant positive association between total vitamin D intake and risk of
endometrioid ovarian cancer8. We speculated however that the inverse association between
vitamin D intake and endometrioid ovarian cancer risk is biologically plausible based on the
known increased risk for endometrioid ovarian tumors with a higher body mass index
(BMI)46, 47. A recent pooled analysis found a stronger inverse association between
circulating 25-hydroxyvitamin D levels and ovarian cancer risk among women with a BMI ≥
2548. Further studies are needed to evaluate whether a high vitamin D intake may be
important for the prevention of endometrioid ovarian tumors among women with a higher
BMI.
Potential limitations of this study include potential differences in the reported diet due to
disease status and the highly correlated nature of dairy related nutrients. However, we
observed an increased ovarian cancer risk with high intake of certain dairy foods (whole
milk, cream cheese) and a decreased risk with others (including consumption of skim/low
fat milk, yogurt), indicating that cases did not consistently under- or over-report their dairy
food intake. Levels of intake of dairy nutrients were highly correlated which can be
problematic in attempts to isolate their mechanistic effects, particularly when lactose is
postulated to increase ovarian cancer risk while calcium and vitamin D were inversely
associated with risk. To address this issue we evaluated the dairy nutrients simultaneously in
the same model, however even using this approach it is possible that residual confounding
could explain some of the observed associations. Lastly, we cannot exclude the possibility
that components of dairy foods other than lactose, vitamin D or calcium might explain the
observed associations with ovarian cancer risk, however these dairy nutrients were selected
a priori based on their potential role in ovarian carcinogenesis.
In conclusion, we found that high intake of certain dairy foods was inversely associated with
ovarian cancer risk (skim/low fat milk, yogurt, cheeses) while increased consumption of
other foods (whole milk, cream cheese) was associated with increased risk. Analyses of
dairy nutrients identified a significant inverse association with high intake of total calcium
(dietary plus supplements) for ovarian cancer risk overall. Furthermore, increased intake of
total calcium was significantly inversely associated with risk of serous borderline and
mucinous tumors, while high intake of total vitamin D was significantly protective for
serous borderline and endometrioid tumors. Future studies are needed to confirm the role of
calcium and vitamin D in the prevention of these specific histological subtypes of ovarian
cancer. If these findings are confirmed in future studies, increasing intakes of calcium and/or
vitamin D may be important factors to consider for the prevention of epithelial ovarian
cancer.
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Abbreviations
OR Odds Ratio
CI 95% confidence interval
NECC New England case-control
FFQ study, food frequency questionnaire
PLR polytomous logistic regression
OC oral contraceptive
Q1 quartile 1
VDR etc, vitamin D receptor
BMI body mass index
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Novelty and impact
Inconsistent results for the role of dairy food intake in relation to ovarian cancer risk may
reflect the potential conflicting effects of lactose, which may increase gonadotropin
levels, and the beneficial anti-proliferative effects of calcium and vitamin D. We provide
evidence of an overall inverse association with high intake of calcium, and identify novel
inverse associations for calcium and vitamin D intake with specific histological subtypes
of ovarian cancer.
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Table 1
Descriptive characteristics of ovarian cancer cases and controls in the New England case-control (NECC)
study
Population Characteristics Cases Controls
Participants, n 1909 1989
Mean (SD)
Age (yrs) 1 52.5 (12.3) 52.4 (12.5)
Parity among parous women 2.5 (1.3) 2.7 (1.4)
Duration of breastfeeding (yrs) 2 0.5 (0.9) 0.7 (1.2)
Duration of oral contraceptive pill use (yrs) 3 4.7 (4.8) 5.7 (5.0)
BMI (kg/ m2) 26.4 (6.2) 26.0 (5.5)
Total calories (kcal) 1886.6 (574.0) 1851.3 (563.2)
Num (%)
Parous 1294 (67.8) 1637 (82.3)
Ever use of oral contraceptives 4 1002 (52.5) 1263 (63.5)
History of tubal ligation 256 (13.4) 392 (19.7)
Family history of ovarian cancer 90 (4.7) 54 (2.7)
Nutrient intake 5, mean (SD)
Lactose (g/d) 13.3 (10.0) 13.6 (9.6)
Dietary calcium (mg/d) 694.9 (256.4) 724.2 (255.5)
Total calcium (mg/d) 967.3 (471.5) 1036.0 (499.5)
Dietary vitamin D (IU/d) 177.9 (112.3) 185.8 (154.1)
Total vitamin D (IU/d) 375.9 (281.7) 392.1 (288.8)
Tumor histology, num (%)
Serous borderline 225 (11.8)
Serous Invasive 792 (41.5)
Mucinous 217 (11.4)
Endometrioid 305 (16.0)
Clear Cell 243 (12.7)
Other 90 (4.7)
Undifferentiated 37 (1.9)
1Cases and controls were frequency-matched on age.
2
Duration of breastfeeding among parous women.
3
Duration of oral contraceptive use among ever users.
4
Ever users used oral contraceptives for >3 months.
5
Reported values are the energy-adjusted nutrient intake.
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